Latest studies
- Active not recruitingPHASE3
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
This study looks into a new tablet medicine, upadacitinib, for adults and teenagers with a type of vitiligo. Researchers want to see how safe it is and how well it helps improve skin when compared to a dummy pill or light therapy.
VitiligoChina - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
Endometrial CancerChina - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
This study looks at a new drug, claseprubart, for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see if the drug helps people with CIDP and if it's safe. Some participants will receive the drug, and others a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyChina - RecruitingPHASE3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This study is testing a new medicine, lunsekimig, for adults aged 40-80 with COPD that's not well-controlled. We want to see if it helps improve breathing, is safe, and has manageable side effects compared to a dummy medicine.
Chronic Obstructive Pulmonary DiseaseChina - RecruitingPHASE1, PHASE2
A Study of YL201 in Patients With Advanced Solid Tumors
This study is testing a new medicine, YL201, for people with advanced cancers that haven't responded to other treatments. It will check if YL201 is safe and how well it works, sometimes given alongside another medicine called atezolizumab. It's an early-stage study happening in China and the US.
Advanced Solid TumorChina - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
DLBCLDiffuse Large B-Cell LymphomaChina - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerChina - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
This study looks at a new drug called anifrolumab for adults with muscle conditions like polymyositis or dermatomyositis. Researchers want to see if it's safe and helps improve symptoms when added to their usual treatment.
Polymyositis, DermatomyositisChina - Active not recruitingPHASE3
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
This study, called TRAILRUNNER-ALZ 3, is looking at a new medicine called Remternetug for people in the early stages of Alzheimer's disease. Researchers want to see if it can slow down memory, thinking, or daily living problems compared to a dummy drug (placebo).
Alzheimer's DiseaseChina - RecruitingPHASE1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
This study is looking at a new drug, RO7673396, for advanced cancers with a specific gene change (RAS mutation). We want to check if it's safe and how the body handles it. We'll also see if it helps shrink tumors.
NeoplasmsChina - RecruitingPHASE3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
This study looks at the long-term safety of a new medicine, ianalumab, for people with lupus. It's for those who have already been in an earlier ianalumab study and continues to check how safe and well the medicine is tolerated over time.
Systemic Lupus ErythematosusChina - Active not recruitingPHASE1
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
This study looks at a new drug, KFA115, on its own and with another drug, pembrolizumab, for various advanced cancers. It aims to find a safe and effective dose, helping doctors understand how these treatments work.
Carcinoma, Non-Small-Cell LungCutaneous MelanomaCarcinoma, Renal CellCarcinoma, Ovarian EpithelialChina - Recruiting
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
This study looks at how well Boston Scientific's special drug-coated devices work in treating blood vessel problems in people's arms and legs. It helps doctors understand their real-world use for conditions like Peripheral Vascular Disease.
Peripheral Vascular DiseasesChina - Active not recruitingPHASE1
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
This study, called MTAPESTRY 104, is testing a new drug called Anvumetostat, alone or with other treatments, for advanced lung cancers that have a specific genetic change (MTAP-deletion). It aims to find the safest and most effective dose.
Thoracic TumorsNon-small Cell Lung CancerChina - Active not recruiting
Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via Radiomics
This study uses a special computer program with artificial intelligence to look at old CT scans of patients. It aims to help doctors tell the difference between retroperitoneal fibrosis, sarcoma, and other diseases found in the back of the tummy. This could lead to faster, easier diagnosis.
Retroperitoneal SarcomaRetroperitoneal FibrosisChina - Active not recruitingPHASE3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
This study looks at a new drug, DB-1303/BNT323, for advanced breast cancer that's 'HER2-low' and hormone-positive. It compares the new drug to standard chemotherapy to see if it can stop the cancer from growing for longer.
Metastatic Breast CancerChina - RecruitingPHASE3
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
This study is looking at a new medicine called maribavir for children and teenagers who have had an organ or stem cell transplant and have a cytomegalovirus (CMV) infection. We want to check if it's safe, how well it works, and find the best dose.
Cytomegalovirus (CMV)China - Active not recruitingPHASE3
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
This study is looking at a new combination of medicines, belrestotug and dostarlimab, for people with a certain type of lung cancer that hasn't been treated before. It compares this combination to a standard treatment (pembrolizumab) and a dummy drug (placebo).
Lung Cancer, Non-Small CellChina - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
Hepatocellular CarcinomaChina - Active not recruitingPHASE3
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
This study looks at a new medicine called Luspatercept for adults with a certain type of blood disorder (MDS) who have anaemia but don't yet need blood transfusions. It compares Luspatercept to another common medicine, Epoetin Alfa, to see which is better and safer.
Myelodysplastic SyndromesChina - Active not recruitingPHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
This study is testing new treatments for liver cancer (hepatocellular carcinoma) in people who have had their cancer removed but are at high risk of it coming back. It compares a drug called durvalumab, alone or with bevacizumab, against a dummy treatment (placebo) to see if they can prevent the cancer from returning.
Hepatocellular CarcinomaChina - Not yet recruitingPHASE2
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
This study looks at a new combination treatment for advanced bowel cancer that has spread. It combines a new drug, VVD-133214, with an existing immunotherapy, pembrolizumab. The aim is to see if this combination works better than pembrolizumab alone for certain types of bowel cancer.
Colorectal AdenocarcinomaChina - RecruitingPHASE3
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study is testing new ways to treat advanced bowel cancer (colorectal cancer) that has spread to other parts of the body. It compares a new drug, Precem-TcT, alone or with another treatment called bevacizumab, against a standard treatment, to see which works best.
Metastatic Colorectal CancerChina - Active not recruitingPHASE2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
This study is testing a new medicine, Volixibat, for people with Primary Biliary Cholangitis (PBC) who experience bothersome itching. We want to see if Volixibat can reduce itching and if it affects how PBC develops. It's a Phase 2 study, meaning we're still learning about its effects.
Primary Biliary CholangitisPBCChina - RecruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
Diffuse Large B-Cell LymphomaChina - RecruitingPHASE2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This study is testing a new medicine, AZD6793, for people with moderate to very severe COPD. It will compare different doses of the medicine against a dummy pill to see if it helps and is safe.
Chronic Obstructive Pulmonary Disease (COPD)China - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
Colon AdenocarcinomaRectal AdenocarcinomaChina - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
Non Small Cell Lung CancerChina - Active not recruitingPHASE3
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
This study is testing a new medicine called Mim8 for people with haemophilia A, including those with inhibitors. Mim8 aims to prevent bleeding episodes by helping blood clot. It's for people already in other Mim8 studies.
Haemophilia AHaemophilia A With InhibitorsChina - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
This study is testing new medicines, Gocatamig and Ifinatamab Deruxtecan (I-DXd), for advanced small cell lung cancer that has come back or isn't responding to treatment. Researchers want to see if these drugs, alone or together, are safe and can shrink the cancer.
Small Cell Lung CancerChina - RecruitingPHASE3
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This study is looking at a new medicine called Elecoglipron for people with certain types of heart failure. It compares Elecoglipron to a dummy medicine (placebo) to see if it helps improve heart health outcomes for adults already taking other heart failure medications, including dapagliflozin.
Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)China - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerChina - RecruitingPHASE3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
This study compares a new medicine, Elecoglipron, to an existing one, Semaglutide, for adults with Type 2 Diabetes. It aims to see if the new drug is safe and effective for people whose diabetes isn't well-controlled and who have a higher risk of heart problems.
Type 2 Diabetes MellitusChina - RecruitingPHASE3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
This study is looking into a new medication called Elecoglipron for weight management. It's for adults who are overweight or have obesity, with or without Type 2 diabetes, to see if it helps them lose weight safely when combined with diet and exercise.
Weight ManagementChina - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
Relapsed or Refractory Multiple MyelomaChina - Active not recruitingPHASE3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
This study, called ARTEMIS, is testing a new medicine called ziltivekimab for people who have had a heart attack. It aims to see if ziltivekimab can prevent future heart problems compared to a dummy medicine.
Cardiovascular RiskAcute Myocardial Infarction (AMI)China - RecruitingPHASE3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
This study is looking at a new medicine called Teplizumab for people aged 1 to 25 with a recent diagnosis of Stage 3 Type 1 Diabetes. It compares Teplizumab to a dummy medicine to see if it makes managing blood sugar easier and reduces how much insulin they need.
Type 1 Diabetes MellitusChina - RecruitingPHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This study looks at a new medicine called elecoglipron for people with long-term kidney disease. We want to see if it helps improve health compared to a dummy pill (placebo). Participants will also be taking existing kidney disease treatments like dapagliflozin. It's a large study, involving many people to get clear results.
Chronic Kidney DiseaseChina - RecruitingPHASE2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
This study is looking for a new way to treat a type of arthritis called radiographic axial spondyloarthritis (r-axSpA). Researchers want to see if an experimental medicine, tulisokibart, can help reduce pain, stiffness, and swelling in the spine and hips for people with this condition.
Radiographic Axial SpondyloarthritisChina - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal CancerChina - RecruitingPHASE3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
This study looks at how safe and effective a medicine called mezagitamab is for adults with a bleeding condition called ITP. If you’ve been in a previous mezagitamab study, you might be invited to join this longer follow-up.
Immune Thrombocytopenic Purpura (ITP)China - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseChina - RecruitingPHASE3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
This study looks at the long-term safety and how well a medicine called belimumab works for people with lung problems linked to certain conditions like lupus. It's for people who've already been in a previous study.
Connective Tissue DiseasesChina - RecruitingPHASE1, PHASE2
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
This study is testing a new drug, BAY 3713372, for certain solid tumours that are missing a specific gene (MTAP-deleted). It aims to find a safe dose, understand how it works in the body, and see if it can shrink these tumours.
MTAP-deleted Solid TumorsChina - RecruitingPHASE2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is looking into a new medicine called Ianalumab for people in the UK with a specific type of scleroderma called diffuse cutaneous systemic sclerosis. It aims to see if the drug is safe and helps with symptoms, compared to a dummy treatment.
Diffuse Cutaneous Systemic SclerosisChina - RecruitingPHASE3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
This study looks at a medicine called ritlecitinib for children with severe alopecia areata, a condition causing hair loss. It checks if the medicine is safe and works over a long time for children who have been in previous studies.
Severe Alopecia AreataChina - RecruitingPHASE4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
This study is for people with multiple myeloma who are already taking elranatamab in a previous study and benefiting from it. It allows them to continue getting the medicine if it's helping them.
Multiple MyelomaChina - RecruitingPHASE3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
This study looks at the long-term safety and effectiveness of a new medicine, marstacimab, for people with haemophilia A or B. It includes patients who already took part in earlier studies of this medicine.
Hemophilia AHemophilia BChina - Active not recruitingPHASE3
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
This study compares a new treatment, TAR-200, with standard chemotherapy for a type of bladder cancer that has returned after initial treatment. It's for people who can't or won't have surgery to remove their bladder.
Non-Muscle Invasive Bladder NeoplasmsChina - RecruitingPHASE2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine, talquetamab, for people with multiple myeloma that has come back or isn't responding to other treatments. The main goal is to see how well it works and if it's safe at the recommended doses.
Hematological MalignanciesChina